Abstract 16791: Comparison of Efficacy and Safety between Sirolimus, Paclitaxel, Everolimus-Eluting Stent and SeQuent™ Please, a Drug-Eluting Balloon on the Outcome of Patients with Diffuse In-Stent Restenosis after Bare Metal Stent Implantation
Purpose: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Everolimus-eluting stent (EES) and SeQuent™ Please, a drug-eluting balloon (DEB) on the outcome of patients with diffuse in-stent restenosis (D-ISR) after bare metal stent (BMS) implantation.
Methods: A prospective analysis of 911 patients with 1080 D-ISR lesions (384 SES, 334 PES, 221 EES and 141 DEB) in six high volume Asian centers after successful stent implantation (SES: LAD 45.7%, LCX 27.8%, RCA 26.5%) (PES: LAD 46.1%, LCX 22.9%, RCA 31.0%) (EES: LAD 50.0%, LCX 21.3%, RCA 28.7%) (DEB: LAD 54.1%, LCX 22.8%, RCA 23.1%) was performed. The study endpoints were major adverse cardiac events (MACE) at 12 months, restenosis rate and target lesion revascularization (TLR) at 12 months.
Results: See table for clinical results.
Conclusions: (1) The use of SES, PES, EES and DEB in patients with D-ISR seems to be favorable in terms of in-hospital clinical outcome. (2) Patients treated with DEB showed higher restenosis rate and TLR compared with DES.
- © 2010 by American Heart Association, Inc.